Who has invested in Immutrin?

Cambridge Innovation Capital are named among the investors backing Immutrin.

Immutrin Funding: $87M Raised, Series A (2026)

Immutrin funding overview

Immutrin is based in Cambridge, United Kingdom. Immutrin has raised $87M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in March 2026. The round record for Immutrin runs through 2026; nothing later has been disclosed. Investors on record include Cambridge Innovation Capital.

Immutrin at a glance

Total raised: $87M
Latest round: Series A
Latest round date: March 2026
Headquarters: Cambridge, United Kingdom
Notable investors: Cambridge Innovation Capital

Frequently asked about Immutrin funding

How much has Immutrin raised?: Immutrin has raised $87M in total disclosed funding across the rounds on record.
Who has invested in Immutrin?: Cambridge Innovation Capital are named among the investors backing Immutrin.
What was the latest Immutrin funding round?: The most recent disclosed round is a Series A, announced in March 2026.
Where is Immutrin based?: Immutrin is based in Cambridge, United Kingdom.
When did Immutrin last raise?: The last disclosed Immutrin round closed in March 2026 at Series A.

Every Immutrin figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Cambridge at a similar stage.

Immutrin Funding: $87M Raised, Series A (2026)

Immutrin funding overview

Immutrin at a glance

Frequently asked about Immutrin funding

Companies related to Immutrin (30)

Browse related funding lists (6)